These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 34613592)

  • 21. Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key.
    Dharmani P; Chadee K
    Curr Mol Pharmacol; 2008 Nov; 1(3):195-212. PubMed ID: 20021434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-integrin therapies.
    Dotan I; Allez M; Danese S; Keir M; Tole S; McBride J
    Med Res Rev; 2020 Jan; 40(1):245-262. PubMed ID: 31215680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-adhesion molecule therapies in inflammatory bowel disease: touch and go.
    Stefanelli T; Malesci A; De La Rue SA; Danese S
    Autoimmun Rev; 2008 May; 7(5):364-9. PubMed ID: 18486923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting Immune Cell Trafficking - Insights From Research Models and Implications for Future IBD Therapy.
    Wiendl M; Becker E; Müller TM; Voskens CJ; Neurath MF; Zundler S
    Front Immunol; 2021; 12():656452. PubMed ID: 34017333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s.
    Binder MT; Becker E; Wiendl M; Schleier L; Fuchs F; Leppkes M; Atreya R; Neufert C; Atreya I; Neurath MF; Zundler S
    Inflamm Bowel Dis; 2018 May; 24(6):1237-1250. PubMed ID: 29788362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases.
    Saruta M; Papadakis KA
    Gastroenterol Clin North Am; 2014 Sep; 43(3):581-601. PubMed ID: 25110260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease--an update.
    Cesarini M; Fiorino G
    Expert Rev Clin Immunol; 2013 Apr; 9(4):301-6. PubMed ID: 23557266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More.
    Misselwitz B; Juillerat P; Sulz MC; Siegmund B; Brand S;
    Digestion; 2020; 101 Suppl 1():69-82. PubMed ID: 32570252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
    Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
    Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biologic therapy for inflammatory bowel disease.
    Ardizzone S; Bianchi Porro G
    Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
    Zeissig S; Rosati E; Dowds CM; Aden K; Bethge J; Schulte B; Pan WH; Mishra N; Zuhayra M; Marx M; Paulsen M; Strigli A; Conrad C; Schuldt D; Sinha A; Ebsen H; Kornell SC; Nikolaus S; Arlt A; Kabelitz D; Ellrichmann M; Lützen U; Rosenstiel PC; Franke A; Schreiber S
    Gut; 2019 Jan; 68(1):25-39. PubMed ID: 29730603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases.
    Zundler S; Neurath MF
    Inflamm Bowel Dis; 2017 Apr; 23(4):617-627. PubMed ID: 28296823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New drugs on the horizon for IBD.
    Sands BE
    Dig Dis; 2014; 32 Suppl 1():74-81. PubMed ID: 25531356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Controlling leukocyte trafficking in IBD.
    Veny M; Fernández-Clotet A; Panés J
    Pharmacol Res; 2020 Sep; 159():105050. PubMed ID: 32598943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation.
    Danese S; Semeraro S; Marini M; Roberto I; Armuzzi A; Papa A; Gasbarrini A
    Dig Liver Dis; 2005 Nov; 37(11):811-8. PubMed ID: 16168725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy in inflammatory bowel disease: Novel and emerging treatments.
    Catalan-Serra I; Brenna Ø
    Hum Vaccin Immunother; 2018; 14(11):2597-2611. PubMed ID: 29624476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease.
    Singh H; Grewal N; Arora E; Kumar H; Kakkar AK
    J Nat Sci Biol Med; 2016; 7(1):4-9. PubMed ID: 27003961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A product review of vedolizumab in inflammatory bowel disease.
    Battat R; Dulai PS; Jairath V; Vande Casteele N
    Hum Vaccin Immunother; 2019; 15(10):2482-2490. PubMed ID: 30897022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel therapeutic targets in the treatment of IBD.
    Kaser A; Tilg H
    Expert Opin Ther Targets; 2008 May; 12(5):553-63. PubMed ID: 18410239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.
    Wyant T; Fedyk E; Abhyankar B
    J Crohns Colitis; 2016 Dec; 10(12):1437-1444. PubMed ID: 27252400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.